Natural and synthetic α-methylenelactones and α- methylenelactams with anticancer potential

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 561-572

  Janecka, Anna ^a   Wyrebska, Anna ^a   Gach, Katarzyna ^a   Fichna, Jakub ^a   Janecki, Tomasz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLENE GAMMA LACTONE DERIVATIVE; ANTINEOPLASTIC AGENT; ARGLABIN; ARTABSIN; CARABRANOLIDE; CELL ADHESION MOLECULE; COSTUNOLIDE; CRASSIN; CRASSUMOLIDE A; CYNAROPICRIN; DEOXYELEPHANTOPIN; GLUTATHIONE; HELENALIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCOSTUNOLIDE; MEXICANIN; MICHAOLIDE A; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SANTAMARINE; STRESS ACTIVATED PROTEIN KINASE; SUBAMOLIDE D; SUBAMOLIDE E; TSOONGIANOLIDE E; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNOLEPIN; VERNOMENIN; XANTHATIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARNICA MONTANA; ARTEMISIA ABSINTHIUM; ARTEMISIA MYRIANTHA; ARTICHOKE; B CELL LEUKEMIA; BLADDER CANCER; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARPESIUM FABERI; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; CHRONIC LYMPHATIC LEUKEMIA; CINNAMOMUM SUBAVENIUM; CYTOTOXICITY; DNA METHYLATION; DRUG STRUCTURE; DRUG SYNTHESIS; ELECAMPANE; ELEPHANTOPUS SCABER; ENZYME ACTIVATION; HELENIUM MEXICANUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIVER CELL CARCINOMA; LOBOPHYTUM CRASSUM; LOBOPHYTUM MICHAELAE; LUNG NON SMALL CELL CANCER; MAGNOLIA SIEBOLDII; MEDICINAL PLANT; MELANOMA; METASTASIS; MICROTUBULE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SENECIO TSOONGIANUS; SIGNAL TRANSDUCTION; TANACETUM PARTHENIUM; TANACETUM VULGARE; XANTHIUM ITALICUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG DISCOVERY; HUMANS; LACTAMS; LACTONES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861633609     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.013     Document Type: Review

References (100)

1. G.M. Cragg, and D.J. Newman Plants as a source of anti-cancer agents J. Ethnopharmacol. 100 2005 72 79
2. S. Zhang Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms Curr. Med. Chem. Anticancer Agents 5 2005 239 249
3. B. Pajak Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells Folia Histochem. Cytobiol. 46 2008 129 135
4. K. Koprowska, and M. Czyz Molecular mechanisms of parthenolide's action: old drug with a new face Postepy Hig. Med. Dosw. 64 2010 100 114
5. A. Ghantous What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15 2010 668 678
6. I. Merfort Perspectives on sesquiterpene lactones in inflammation and cancer Curr. Drug Targets 2011 doi:BSP/CDT/E-Pub/00262
7. A.K. Picman Biological activities of sesquiterpene lactones Biochem. Syst. Ecol. 14 1986 255 281
8. R.R.A. Kitson The renaissance of alpha-methylene-gamma-butyrolactones: new synthetic approaches Angew. Chem. Int. Ed. 48 2009 9426 9451
9. H.N. Pati Cytotoxic thiol alkylators Mini Rev. Med. Chem. 7 2007 131 139
10. K.H. Lee, and H. Furukawa Antitumor agents. 3. Synthesis and cytotoxic activity of helenalin amine adducts and related derivatives J. Med. Chem. 15 1972 609 611
11. M.T. Scotti Quantitative structure-activity relationship of sesquiterpene lactones with cytotoxic activity Bioorg. Med. Chem. 15 2007 2927 2934
12. M.L. Guzman An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells Blood 110 2007 4427 4435
13. A.C. Beekman Structure-cytotoxicity relationships of some helenanolide-type sesquiterpene lactones J. Nat. Prod. 60 1997 252 257
14. T.J. Schmidt Helenanolide-type sesquiterpene lactones.2. The molecular conformations of arnifolin and some related helenanolides as determined by X-ray crystallographic and NMR spectroscopic analyses J. Mol. Struct. 385 1996 113 121
15. M.C. Recio In vivo activity of pseudoguaianolide sesquiterpene lactones in acute and chronic inflammation Life Sci. 66 2000 2509 2518
16. M. Karin, and A. Lin NF-kappaB at the crossroads of life and death Nat. Immunol. 3 2002 221 227
17. R. Horie, and T. Watanabe The biological basis of Hodgkin's lymphoma Drug News Perspect. 16 2003 649 656
18. J.T. Wu, and J.G. Kral The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy J. Surg. Res. 123 2005 158 169
19. S.J. Braeuer Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells Mol. Cancer Res. 4 2006 715 728
20. A. Dey Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways Nat. Rev. Drug Discov. 7 2008 1031 1040
21. D. Oka Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB Int. J. Cancer 120 2007 2576 2581
22. Y. Kishida Parthenolide, a natural inhibitor of nuclear factor-kappaB, inhibits lung colonization of murine osteosarcoma cells Clin. Cancer Res. 13 2007 59 67
23. G.G. Ma Inhibition of NF-kappaB-mediated transcription and induction of apoptosis by melampolides and repandolides Cancer Chemother. Pharmacol. 60 2007 35 43
24. A.J. Garcia-Pineres Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential Life Sci. 75 2004 841 856
25. P. Rungeler Inhibition of transcription factor NF-kappaB by sesquiterpene lactones: a proposed molecular mechanism of action Bioorg. Med. Chem. 7 1999 2343 2352
26. J.H. Kim Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis Cancer Res. 65 2005 6312 6320
27. C.J. Sweeney The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer Mol. Cancer Ther. 4 2005 1004 1012
28. G. Pearson Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr. Rev. 22 2001 153 183
29. N.H. Nam Naturally occurring NF-kappaB inhibitors Mini Rev. Med. Chem. 6 2006 945 951
30. T.M. Hung Cholinesterase inhibitory and anti-amnesic activity of alkaloids from Corydalis turtschaninovii J. Ethnopharmacol. 119 2008 74 80
31. J.S. Kang Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells Biochem. Biophys. Res. Commun. 313 2004 171 177
32. P.T. Schumacker Reactive oxygen species in cancer cells: live by the sword, die by the sword Cancer Cell 10 2006 175 176
33. L. Chaiswing Extracellular redox state regulates features associated with prostate cancer cell invasion Cancer Res. 68 2008 5820 5826
34. J. Wen Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide J. Biol. Chem. 277 2002 38954 38964
35. W. Ou, and J. Silver Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion Virology 350 2006 406 417
36. K.A. Gelderman T cell surface redox levels determine T cell reactivity and arthritis susceptibility Proc. Natl. Acad. Sci. U. S. A. 103 2006 12831 12836
37. Y.K. Won Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms Carcinogenesis 25 2004 1449 1458
38. H. Yao Parthenolide protects human lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9 Cell Res. 17 2007 565 571
39. J. Skalska Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide PLoS One 4 2009 e8115
40. M.L. Guzman The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells Blood 105 2005 4163 4169
41. B.T. Kawasaki Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach Prostate 69 2009 827 837
42. J.H. Choi, and K.T. Lee Costunolide-induced apoptosis in human leukemia cells: involvement of c-jun N-terminal kinase activation Biol. Pharm. Bull. 32 2009 1803 1808
43. R. Bai Mapping the binding site of colchicinoids on beta-tubulin. 2-chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354 J. Biol. Chem. 275 2000 40443 40452
44. Z.W. Gao Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models Curr. Cancer Drug Targets 10 2010 705 715
45. X. Fonrose Parthenolide inhibits tubulin carboxypeptidase activity Cancer Res. 67 2007 3371 3378
46. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discov. 5 2006 37 50
47. Z. Liu Modulation of DNA methylation by a sesquiterpene lactone parthenolide J. Pharmacol. Exp. Ther. 329 2009 505 514
48. H. Nakshatri Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase Oncogene 23 2004 7330 7344
49. M.C. Ralstin Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest Mol. Cancer Res. 4 2006 387 399
50. D. Carlisi Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation J. Cell. Physiol. 226 2011 1632 1641
51. M. Czyz Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells Br. J. Pharmacol. 160 2010 1144 1157
52. J.W. Liu Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro J. Exp. Clin. Cancer Res. 29 2010 108
53. R. Shanmugam A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species Prostate 70 2010 1074 1086
54. R. Shanmugam A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species Int. J. Cancer 128 2011 2481 2494
55. J. Sahler The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-kappaB inhibition Thromb. Res. 127 2011 426 434
56. J.L. Hsu Costunolide induces apoptosis through nuclear calcium(2+) overload and DNA damage response in human prostate cancer J. Urol. 185 2011 1967 1974
57. S. Kanno Costunolide-induced apoptosis is caused by receptor-mediated pathway and inhibition of telomerase activity in NALM-6 cells Biol. Pharm. Bull. 31 2008 1024 1028
58. C.N. Chen Isocostunolide, a sesquiterpene lactone, induces mitochondrial membrane depolarization and caspase-dependent apoptosis in human melanoma cells Cancer Lett. 246 2007 237 252
59. J.H. Cardellina, and R.E. Moore Structures of pukeleimide-A, pukeleimide-B, pukeleimide-D, pukeleimide-E, pukeleimide-F, and pukeleimide-G Tetrahedron Lett. 22 1979 2007 2010
60. C.C. Huang Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice Br. J. Pharmacol. 159 2010 856 871
61. C. Berges Helenalin suppresses essential immune functions of activated CD4+ T cells by multiple mechanisms Mol. Immunol. 46 2009 2892 2901
62. J.Y. Cho Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines Eur. J. Pharmacol. 492 2004 85 94
63. B. Schnyder Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1 Biochem. Biophys. Res. Commun. 292 2002 841 847
64. S.J. Jeong Costunolide, a sesquiterpene lactone from Saussurea lappa, inhibits the VEGFR KDR/Flk-1 signaling pathway Cancer Lett. 187 2002 129 133
65. A.I. Idris Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo Mol. Cancer Ther. 8 2009 2339 2347
66. S.M. Kupchan Vernolepin, a novel elemanolide dilactone tumor inhibitor from Vernonia hymenolepis J. Am. Chem. Soc. 90 1968 3596 3597
67. A.J. Weinheimer Naturally occurring cembranes Fortschr. Chem. Org. Naturst. 36 1979 285
68. T. Naito Total syntheses of (+/-)-anantine and (+/-)-isoanantine via thiyl radical addition-cyclization reaction Chem. Pharm. Bull. 41 1993 217 219
69. C. Belaud Synthesis of potential cytotoxic alpha-methylene gamma-lactams Synth. Commun. 15 1985 1233 1243
70. M.J. Kornet Synthesis of alpha-methylenebeutyrolactams as potential antitumor agents J. Pharm. Sci. 68 1979 350 353
71. H. Ikuta Synthesis and anti-inflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones J. Med. Chem. 30 1987 1995 1998
72. Z. Zhang Gelegamines A-E: five new oxindole alkaloids from Gelsemium elegans Tetrahedron 65 2009 4551 4556
73. K.H. Lee Synthesis and anticancer evaluation of certain alpha-methylene-gamma-(4-substituted phenyl)-gamma-butyrolactone bearing thymine, uracil, and 5-bromouracil Bioorg. Med. Chem. Lett. 9 1999 241 244
74. A. bu-Daya DNA sequence preferences of several AT-selective minor groove binding ligands Nucleic Acids Res. 23 1995 3385 3392
75. P.G. Baraldi Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders J. Med. Chem. 47 2004 2877 2886
76. S. Nasim, and P.A. Crooks Antileukemic activity of aminoparthenolide analogs Bioorg. Med. Chem. Lett. 18 2008 3870 3873
77. S. Neelakantan Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1) Bioorg. Med. Chem. Lett. 19 2009 4346 4349
78. A. Albrecht Recent advances in the synthesis of alpha-alkylidene- substituted delta-lactones, gamma-lactams and delta-lactams Eur. J. Org. Chem. 15 2011 2747 2766
79. T.G. Elford Diversity-oriented synthesis and preliminary biological screening of highly substituted five-membered lactones and lactams originating from an allyboration of aldehydes and imines J. Comb. Chem. 11 2009 155 168
80. T.L. Born Enzyme-catalyzed acylation of homoserine: mechanistic characterization of the Haemophilus influenzae met2-encoded homoserine transacetylase Biochemistry 39 2000 8556 8564
81. M. Josa Pharmacokinetic/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat J. Pharmacol. Exp. Ther. 297 2001 198 205
82. A.G. Gonzalez Synthesis and antiproliferative activity of a new compound containing an alpha-methylene-gamma-lactone group J. Med. Chem. 45 2002 2358 2361
83. T. Janecki New stereocontrolled synthesis and biological evaluation of 5-(1′-hydroxyalkyl)-3-methylidenetetrahydro-2-furanones as potential cytotoxic agents J. Med. Chem. 45 2002 1142 1145
84. T. Janecki Enantioselective synthesis and cytotoxic evaluation of 4,5-dihydro-5-[aryl(hydroxy)methyl]-3-methylidenefuran-2(3H)-ones Chem. Biodivers. 2 2005 1256 1265
85. T. Janecki Novel synthesis, cytotoxic evaluation, and structure-activity relationship studies of a series of alpha-alkylidene-gamma-lactones and lactams J. Med. Chem. 48 2005 3516 3521
86. A. Albrecht Synthesis and cytotoxic activity of gamma-aryl substituted alpha-alkylidene-gamma-lactones and alpha-alkylidene-gamma-lactams Bioorg. Med. Chem. 16 2008 4872 4882
87. A. Albrecht A convenient synthesis and cytotoxic evaluation of beta-aryl-alpha-methylidene-gamma-lactones and beta-aryl-alpha-methylidene- gamma-lactams New J. Chem. 34 2010 750 761
88. L. Albrecht Synthesis and cytotoxic evaluation of beta-alkyl or beta-aryl-delta-methyl-alpha-methylene-delta-lactones. Comparison with the corresponding gamma-lactones Eur. J. Med. Chem. 45 2010 710 718
89. T. Janecki 4-Methylideneisoxazolidin-5-ones - a new class of alpha-methylidene-gamma-lactones with high cytostatic activity Bioorg. Med. Chem. Lett. 16 2006 1430 1433
90. M. Rozalski Synthesis and biological evaluation of 4- methylideneisoxazolidin-5-ones - a new class of highly cytotoxic alpha-methylidene-gamma-lactones Eur. J. Med. Chem. 42 2007 248 255
91. P.V. Ramachandran Tailored alpha-methylene-gamma-butyrolactones and their effects on growth suppression in pancreatic carcinoma cells Bioorg. Med. Chem. Lett. 20 2010 6620 6623
92. I. Sohma Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer Cancer Genomics Proteomics 8 2011 39 47
93. A. Zanotto-Filho NFkappaB inhibitors induce cell death in glioblastomas Biochem. Pharmacol. 81 2011 412 424
94. D.C. Hassane Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways Blood 116 2010 5983 5990
95. A.J. Steele The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro Leukemia 20 2006 1073 1079
96. M.T. Yip-Schneider Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells Mol. Cancer Ther. 4 2005 587 594
97. W. Wang A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells Pancreas 38 2009 e114 e123
98. M.T. Yip-Schneider Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer Pancreas 37 2008 e45 e53
99. N.S. Zhangabylov Sesquiterpene lactone arglabin influences DNA synthesis in P388 leukemia cells in vivo Pharm. Chem. J. 38 2004 651 653
100. R.B. Riggins The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells Mol. Cancer Ther. 4 2005 33 41